Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes
The STEP 1 extension study showed that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year
A 2,700person realworld study presented at the 2025 European Congress on Obesity showed an average 16% weightloss over 64 weeks at microdose levels of semaglutide
McCall McPhereson: Yeah, so I will tell you in our program and our program is based in a model For short term [00:13:00] use with the exception of people who have a pretty life changing experience from an inflammatory standpoint
A summary of GLP-1 RAs effects on inflammatory patterns is reported in Fig
Metabolic Benefits Beyond Weight Loss Weight loss gets the headlines, but the metabolic improvements may matter even more for long-term health outcomes